Aurora Cannabis Inc (ACB) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Aurora Cannabis Inc $3.55, price $4.16, upside -14.7%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Aurora Cannabis Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $2.58 – $93.50 · fair‑value band $2.34 – $4.43 · the $4.16 price screens above the $3.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Aurora Cannabis in your weekly email
Every Wednesday you see whether Aurora Cannabis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation.
Show more
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers pharmaceutical-grade cannabis products; medical and consumer cannabis products; and engages in the propagation of vegetables and floral plants. It also provides dried and fresh cannabis, cannabis oils, trims, concentrates, ingestibles, capsules, vaporizers, edible cannabis, cannabis extracts, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes San Rafael '71, Greybeard, Drift, Daily Special, Being, CanniMed, MedReleaf, Aurora, and WMMC, as well as international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.
Stock analysis
Aurora Cannabis Inc (ACB) currently trades at $4.16, while our model-based Fair Value estimate is $3.55, implying the stock looks roughly 17.2% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $2.34 (bear) to $4.43 (bull), the price of $4.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Aurora Cannabis Inc reported revenue of C$321M in FY2026 versus C$221M in FY2022, a compound +9.8%/yr. Reported net income was −C$122M in FY2026.
Key figures
Market cap $236M · P/S ratio 0.56 · EPS (TTM) $−0.7400 · Net margin −38.0% · Return on equity −10.5% · Return on assets (EBIT) −15.9% · Operating margin −26.4% · Revenue (TTM) C$321M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (medium confidence).
What moves the price
The share trades about 33% below its 52-week high and 61% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −15%, ACB screens richer than that median.
Fair Value models
Bear $2.34Fair Value $3.55Bull $4.43
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.9/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2021 (pandemic). Over 10 years: +71.8% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.4%
’09
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−115.3% (2021) → −50.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (93 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−15% · Below median
Profitability
Return on assets−4% · Bottom 25%
Net margin (TTM)−42% · Bottom 25%
Operating margin (TTM)−26% · Bottom 25%
Growth and dividend
Revenue growth5% · Above median
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Aurora Cannabis Inc (ACB) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $3.55 versus a price of $4.16, about −15% upside (overvalued).
What is the fair value of ACB?
Our model-based fair value for Aurora Cannabis Inc is $3.55 (as of Sep 23, 2026), built from audited fundamentals. The current price: $4.16.
What is the quality score of ACB?
Aurora Cannabis Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aurora Cannabis Inc (ACB)?
Our model-based price target is the fair value of $3.55 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $2.34, optimistic scenario $4.43. It is a calculation from audited fundamentals, not an analyst target.
What is the Aurora Cannabis Inc stock forecast for 2026?
Our models put fair value at $3.55, about −15% upside versus a price of $4.16 (overvalued). Cautious scenario $2.34, optimistic scenario $4.43. The calculation is refreshed regularly with new filings.
What is the revenue of Aurora Cannabis Inc (ACB)?
Aurora Cannabis Inc reported trailing-twelve-month revenue of about C$321M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Aurora Cannabis Inc (ACB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aurora Cannabis Inc it is $3.55 per share (as of Sep 23, 2026), against a price of $4.16. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aurora Cannabis Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ACB trades above its calculated fair value: price $4.16, fair value $3.55, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACB?
No. The price is what the market pays today ($4.16); the fair value is what the company's own numbers justify ($3.55). For Aurora Cannabis Inc the two are $0.6100 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aurora Cannabis Inc worth?
The market values Aurora Cannabis Inc at about $236M (market capitalisation, as of Sep 23, 2026). Per share that is $4.16; our models calculate a fair value of $3.55 per share.
What do the bullish and bearish scenarios say about ACB?
Our models span a range for Aurora Cannabis Inc: cautious scenario $2.34, base $3.55, optimistic $4.43 per share (as of Sep 23, 2026, price $4.16). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aurora Cannabis Inc (ACB)?
Balance-sheet figures for Aurora Cannabis Inc (as of Sep 23, 2026): return on equity −10.5%, debt of 0.08 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is ACB from its 52-week high?
Aurora Cannabis Inc trades at $4.16, about 33% below its 52-week high of $6.23 and 61% above the low of $2.58 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $3.55 is for.
Which stocks are comparable to Aurora Cannabis Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aurora Cannabis Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $4.16, calculated fair value $3.55 (−15%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACB calculated?
We run Aurora Cannabis Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.55, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Aurora Cannabis Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aurora Cannabis Inc (ACB)?
The closing price on Sep 24, 2026 was $4.16. Our model-based fair value is $3.55, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aurora Cannabis Inc right now?
A fairly wide model range ($2.34 to $4.43) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Aurora Cannabis Inc
How large is the market capitalisation of Aurora Cannabis Inc (ACB)?
The market capitalisation of Aurora Cannabis Inc is $236M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aurora Cannabis Inc (ACB)?
The price-to-sales ratio of Aurora Cannabis Inc is 0.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aurora Cannabis Inc (ACB)?
Earnings per share at Aurora Cannabis Inc are $−0.7400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aurora Cannabis Inc (ACB)?
The net margin of Aurora Cannabis Inc is −38.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aurora Cannabis Inc (ACB)?
The return on equity (ROE) of Aurora Cannabis Inc is −10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aurora Cannabis Inc (ACB)?
On an EBIT basis the return on assets of Aurora Cannabis Inc is −15.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aurora Cannabis Inc (ACB)?
The operating margin of Aurora Cannabis Inc is −26.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aurora Cannabis Inc (ACB)?
Revenue at Aurora Cannabis Inc is growing +5.1% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aurora Cannabis Inc (ACB)?
Earnings per share at Aurora Cannabis Inc are growing −94.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aurora Cannabis Inc (ACB) generate?
The free cash flow of Aurora Cannabis Inc is −C$36.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Aurora Cannabis Inc (ACB) hold?
Aurora Cannabis Inc holds more cash than debt, C$88.9M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Aurora Cannabis Inc in the live analysis
One click puts Aurora Cannabis Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026